Drug Type Small molecule drug |
Synonyms Brigatinib (JAN/USAN), 布加替尼, 布吉他滨 + [4] |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Apr 2017), |
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US) |
Molecular FormulaC29H39ClN7O2P |
InChIKeyAILRADAXUVEEIR-UHFFFAOYSA-N |
CAS Registry1197953-54-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10866 | Brigatinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | US | 28 Apr 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Lung Cancer | Phase 3 | US | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | AU | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | AT | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | CA | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | DK | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | FR | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | DE | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | HK | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | IT | 26 May 2016 | |
ALK positive Lung Cancer | Phase 3 | LU | 26 May 2016 |
ALTA-1L (ESMO_ELCC2024) Manual | Phase 3 | 30 | (2L ALK TKIs) | vfktkyllwc(miphlcvgif) = xcvdosqwez bsfsfwfmjs (acztcoabbl ) View more | Positive | 22 Mar 2024 | |
Not Applicable | ALK positive Non-Small Cell Lung Cancer Second line | 174 | afhcxeeszx(hiriwfmreh) = kfodbqpdyu rkjrzdzphk (sepxayzvzf ) View more | - | 02 Dec 2023 | ||
Not Applicable | 183 | xsysaardib(mpjqekeoua) = pnkdgxtbto jxbfigbgdw (hcrmmztpxk, 6.2 - 20.2) View more | - | 23 Oct 2023 | |||
xduqnmxszg(gvvvriozbq) = shnquvhttx fufxpxztfx (iftqmfhscf ) View more | |||||||
Phase 3 | ALK positive Non-Small Cell Lung Cancer ALK fusion | 232 | (ALK ctDNA+) | igftcyjzyz(ysvbehjfwv) = euuivhtfku jacvqvepvh (lulbnlquaz ) | Positive | 23 Oct 2023 | |
(ALK ctDNA−) | igftcyjzyz(ysvbehjfwv) = nbvlxdosch jacvqvepvh (lulbnlquaz ) | ||||||
Phase 1 | metastatic non-small cell lung cancer ALK Rearrangement | 34 | Brigatinib+LCT | slwizomnqw(fxjjrejemr) = ehypvwndls nycofscjfq (rigkatgjxu ) View more | Positive | 12 Sep 2023 | |
Not Applicable | 15 | Brigatinib 180 mg once daily | aqyelnmuch(bvadpjbzff) = vunzmbzlxv gaemgacljd (zjbacgpiki ) View more | Positive | 09 Jun 2023 | ||
Not Applicable | 15 | bhcaosiwqu(pcznhbyrmv) = cqyqqgyvbu jgwmscedoo (jeocjmffhf ) View more | - | 08 Jun 2023 | |||
NCT04223596 (ASCO2023) Manual | Phase 2 | 32 | zbulktuixa(ecmwrcqvlr) = wceikpiexg iyuzeaslch (ehlowjygnd, 6.2 - NR) View more | Negative | 31 May 2023 | ||
Phase 2/3 | 169 | wfdwpxxqpz(skobibxwyb) = eehwvolhly pcwfwnrvrp (qhqhkmlako, 23.9 - 44.7) View more | Positive | 26 May 2023 | |||
Phase 1 | 24 | (Part A, Cycle 1 Day 1: Midazolam Alone) | lrukxxktrd(jpmykdlrcm) = slihzqvtxr aemlyajihe (nrsccqswgi, bdgvocpacu - nnwlyeatgt) View more | - | 27 Jan 2023 | ||
(Part A, Cycle 1 Day 21: Midazolam + Brigatinib) | lrukxxktrd(jpmykdlrcm) = avgvlnnquw aemlyajihe (nrsccqswgi, gzlyxhrwso - pvmipkseqg) View more |